Abstract
Utilizing the intrinsic optical signal (IOS) of retinal Spreading Depression (rSD) waves and the concomitant transparency changes of the tissue, we show that nicotine, in an in vivo near tissue preparation, has neuroprotective effects against the excitotoxic cell death, mediated through the activation of glutamate-receptors. For this study the retinal tissue was treated with NMDA, an agonist for the NMDA-glutamate-receptor, being excitotoxic at higher concentrations, to induce tissue damage. The protective effects of nicotine against glutamate induced neurotoxicity are demonstrated, comparing the IOS with NMDA and NMDA + nicotine. We additionally present data about the decrease of the propagation velocity of rSD waves after nicotine application and show analogical effects obtained with epibatidine, a specific nicotinic acetylcholine receptor (nAChR) agonist.
Keywords: Epibatidine, excitotoxic cell death, neuroprotection, nicotine, NMDA, spreading depression, analogical effects, (nAChR) agonist, neuroprotective effects
Current Medicinal Chemistry
Title: Neuroprotective Properties of Nicotine
Volume: 19 Issue: 2
Author(s): M. Sieber
Affiliation:
Keywords: Epibatidine, excitotoxic cell death, neuroprotection, nicotine, NMDA, spreading depression, analogical effects, (nAChR) agonist, neuroprotective effects
Abstract: Utilizing the intrinsic optical signal (IOS) of retinal Spreading Depression (rSD) waves and the concomitant transparency changes of the tissue, we show that nicotine, in an in vivo near tissue preparation, has neuroprotective effects against the excitotoxic cell death, mediated through the activation of glutamate-receptors. For this study the retinal tissue was treated with NMDA, an agonist for the NMDA-glutamate-receptor, being excitotoxic at higher concentrations, to induce tissue damage. The protective effects of nicotine against glutamate induced neurotoxicity are demonstrated, comparing the IOS with NMDA and NMDA + nicotine. We additionally present data about the decrease of the propagation velocity of rSD waves after nicotine application and show analogical effects obtained with epibatidine, a specific nicotinic acetylcholine receptor (nAChR) agonist.
Export Options
About this article
Cite this article as:
Sieber M., Neuroprotective Properties of Nicotine, Current Medicinal Chemistry 2012; 19 (2) . https://dx.doi.org/10.2174/092986712803414222
DOI https://dx.doi.org/10.2174/092986712803414222 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures
Current Pharmaceutical Design Study of the cis-trans Isomerization of the Amino-Acyl prolyl Peptide Bond. Application to the Design of Novel Inhibitors of Immunophilins
Current Organic Chemistry Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review
CNS & Neurological Disorders - Drug Targets Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Gastric Inhibitory Polypeptide and its Receptor are Expressed in the Central Nervous System and Support Neuronal Survival
Central Nervous System Agents in Medicinal Chemistry Drugs of Abuse in Pregnancy, Poor Neonatal Development, and Future Neurodegeneration. Is Oxidative Stress the Culprit?
Current Pharmaceutical Design Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design Protein Misfolding in Disease and Small Molecule Therapies
Current Topics in Medicinal Chemistry Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Targeting ENaC as a Molecular Suspect in Cystic Fibrosis
Current Drug Targets A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Computational Methods for De novo Protein Design and its Applications to the Human Immunodeficiency Virus 1, Purine Nucleoside Phosphorylase, Ubiquitin Specific Protease 7, and Histone Demethylases
Current Drug Targets Oxidative Stress and Accelerated Aging in Neurodegenerative and Neuropsychiatric Disorder
Current Pharmaceutical Design subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regional Grey Matter Loss and Brain Disconnection Across Alzheimer Disease Evolution
Current Medicinal Chemistry